{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:49Z","timestamp":1790050969268,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560355"],"award-info":[{"award-number":["82560355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171363"],"award-info":[{"award-number":["32171363"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013114","name":"Yunnan Key Research and Development Program","doi-asserted-by":"publisher","award":["202403AC100014"],"award-info":[{"award-number":["202403AC100014"]}],"id":[{"id":"10.13039\/501100013114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003996","name":"Kunming Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218429","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:45:08Z","timestamp":1773215108000},"page":"218429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A NIR-\u2161 fluorescent probe for real-time visualization and early assessment of responses to CDK4\/6 inhibitors in breast cancer"],"prefix":"10.1016","volume":"646","author":[{"given":"Yi-Yang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Liang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8761-0487","authenticated-orcid":false,"given":"Lin-Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5182-5887","authenticated-orcid":false,"given":"Guo-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218429_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib3","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib7","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib9","series-title":"American Society of Clinical Oncology","author":"Zhang","year":"2024"},{"key":"10.1016\/j.canlet.2026.218429_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251353623","article-title":"Understanding and overcoming CDK4\/6 inhibitor resistance in HR+\/HER2- metastatic breast cancer: clinical and molecular perspectives","volume":"17","author":"da Silva","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218429_bib16","doi-asserted-by":"crossref","first-page":"R337","DOI":"10.1530\/ERC-16-0121","article-title":"Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies","volume":"23","author":"Murphy","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2026.218429_bib17","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41591-025-03935-w","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial","volume":"31","author":"Jongbloed","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218429_bib19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41591-025-03633-7","article-title":"RANO criteria for response assessment of brain metastases based on amino acid PET imaging","volume":"31","author":"Albert","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrc.2017.83","article-title":"Engineering and physical sciences in oncology: challenges and opportunities","volume":"17","author":"Mitchell","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218429_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13058-022-01555-7","article-title":"Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment","volume":"24","author":"Liu","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218429_bib22","doi-asserted-by":"crossref","first-page":"32253","DOI":"10.1021\/acsomega.1c05073","article-title":"Gallium-68 labeling of the cyclin-dependent kinase 4\/6 inhibitors as positron emission tomography radiotracers for tumor imaging","volume":"6","author":"Liu","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.canlet.2026.218429_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2967\/jnumed.119.232603","article-title":"Noninvasive PET imaging of CDK4\/6 activation in breast cancer","volume":"61","author":"Ramos","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.136","article-title":"In vivo visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model","volume":"3","author":"Gao","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218429_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918786451","article-title":"CDK4\/6 inhibition in breast cancer: current practice and future directions","volume":"10","author":"Pernas","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218429_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.msec.2017.08.004","article-title":"Albumin based versatile multifunctional nanocarriers for cancer therapy: fabrication, surface modification, multimodal therapeutics and imaging approaches","volume":"81","author":"Kudarha","year":"2017","journal-title":"Mater. Sci. Eng., C"},{"key":"10.1016\/j.canlet.2026.218429_bib27","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.7150\/thno.19365","article-title":"Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery","volume":"7","author":"An","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218429_bib28","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218429_bib29","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218429_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218429_bib31","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/acs.molpharmaceut.9b00540","article-title":"Synthesis and biological evaluation of novel (99m)Tc-Labeled palbociclib derivatives targeting cyclin-dependent kinase 4\/6 (CDK4\/6) as potential cancer imaging agents","volume":"16","author":"Song","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2026.218429_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112032","article-title":"Preparation and evaluation of (99m)Tc-labeled HYNIC-Palbociclib analogs for cyclin-dependent kinase 4\/6-positive tumor imaging","volume":"188","author":"Gan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218429_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-023-01366-y","article-title":"Molecular and functional imaging in cancer-targeted therapy: current applications and future directions","volume":"8","author":"Bai","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218429_bib35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nprot.2008.52","article-title":"Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways","volume":"3","author":"Zhang","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2026.218429_bib36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1593\/neo.07421","article-title":"Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation","volume":"9","author":"Zhang","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218429_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nm1047","article-title":"Bioluminescent imaging of Cdk2 inhibition in vivo","volume":"10","author":"Zhang","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218429_bib38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7150\/ijbs.52101","article-title":"The G1 phase optical reporter serves as a sensor of CDK4\/6 inhibition in vivo","volume":"17","author":"Guo","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218429_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201900321","article-title":"Near\u2010infrared\u2010II molecular dyes for cancer imaging and surgery","volume":"31","author":"Zhu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.canlet.2026.218429_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202001066","article-title":"Surgical navigation for malignancies guided by near\u2010infrared\u2010II fluorescence imaging","volume":"5","author":"Yang","year":"2021","journal-title":"Small Methods"},{"key":"10.1016\/j.canlet.2026.218429_bib41","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.7150\/thno.27995","article-title":"Near-infrared-II (NIR-II) bioimaging via off-peak NIR-I fluorescence emission","volume":"8","author":"Zhu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218429_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218429_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/940585","article-title":"A review of indocyanine green fluorescent imaging in surgery","volume":"2012","author":"Alander","year":"2012","journal-title":"Int. J. Biomed. Imag."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:39:37Z","timestamp":1776857977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"alternative-id":["S0304383526001928"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218429","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A NIR-\u2161 fluorescent probe for real-time visualization and early assessment of responses to CDK4\/6 inhibitors in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218429"}}